Share on StockTwits
 

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.01, AR Network reports. The company had revenue of $10.60 million for the quarter, compared to the consensus estimate of $8.81 million.

Several analysts have recently commented on the stock. Analysts at Piper Jaffray initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 20th. They set an “overweight” rating and a $17.00 price target on the stock. On a related note, analysts at Mizuho initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 20th. They set a “buy” rating and a $23.00 price target on the stock. Finally, analysts at Needham & Company initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 18th. They set a “buy” rating and a $14.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. BioCryst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $16.20.

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 12.83 on Wednesday. BioCryst Pharmaceuticals has a 52 week low of $1.12 and a 52 week high of $13.33. The stock has a 50-day moving average of $10.47 and a 200-day moving average of $7.42. The company’s market cap is $758.1 million.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.